Fig. 5: Neurogenic differentiation by trametinib in iPSC-derived NSCs from AD patients. | Experimental & Molecular Medicine

Fig. 5: Neurogenic differentiation by trametinib in iPSC-derived NSCs from AD patients.

From: Trametinib activates endogenous neurogenesis and recovers neuropathology in a model of Alzheimer’s disease

Fig. 5

AD patient iPSC-derived NSCs were cultured with 100 nM trametinib for 48 h. a, b Immunofluorescence staining of DCX and NESTIN (a) and quantification data for DCX+ cell or NESTIN+ cell numbers (b). Scale bars, 50 μm. c–e DCX (c), NEUROD1 (d) or TUJ1 (e) were detected using qRT‒PCR. Each sample was normalized to the expression of GAPDH. f–j Cell lysates were subjected to immunoblot analyses of DCX, SOX2, pERKs, ERKs and GAPDH (f) and quantified with band intensities. Normalized by GAPDH band intensity and renormalized to the control group (g–j). Statistical analysis was performed by three independent experiments. P values were obtained by Student’s t-test. *p < 0.05, **p < 0.005 and ***p < 0.001.

Back to article page